

Bepreve - (1.5%; Solution/Drops, Opthalmic)

Generic Name	Bepotastine Besilate	Innovator	BAUSCH AND LOMB INC
Dosage	1.5%; Solution/Drops, Opthalmic	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	Less Than 5
Indication	Bepreve™ is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.		
Complexities	Yes		

Chronology Of Events

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.